Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
On Wednesday, Roth/MKM reiterated its Buy rating on shares of Bio-Path Holdings (NASDAQ:BPTH), maintaining the price target at $20.00. The firm's stance comes after Bio-Path Holdings provided an update on its ongoing clinical trials.
The company reported extended therapy durations for two Phase 2 acute myeloid leukemia (AML) patients. These patients are part of a study examining the efficacy of a triple combination therapy consisting of prexigebersen, venetoclax, and decitabine, and have maintained complete responses (CRs).
The updated results are from the Phase 1/1b trial evaluating prexigebersen-A in solid tumors. The findings highlight the potential of antisense DNA therapy to exhibit antitumor properties. Moreover, the therapy demonstrated a highly favorable safety profile, which is particularly significant for elderly cancer patients who often face greater risks of adverse effects from treatment.
Bio-Path Holdings focuses on the development of therapeutic products based on its proprietary liposomal delivery technology, DNAbilize. The company's product candidates are designed to target cancer and other challenging diseases with novel treatments.
The positive trial results support the company's approach to cancer therapy, which aims to provide effective and safe treatment options for patients, including those who are elderly and may not tolerate traditional cancer therapies well.
The reaffirmed stock price target of $20.00 by Roth/MKM reflects confidence in Bio-Path Holdings' ongoing research and potential market performance. The company's stock continues to be monitored by investors as clinical trials proceed and more data becomes available.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.